SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 229 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,802,000 | -46.1% | 200,000 | -28.3% | 0.06% | -46.1% |
| Q2 2021 | $3,341,000 | -17.3% | 279,100 | -13.5% | 0.12% | -23.3% |
| Q1 2021 | $4,042,000 | -34.0% | 322,600 | -17.8% | 0.15% | -46.2% |
| Q4 2020 | $6,122,000 | +75.1% | 392,300 | +6.0% | 0.28% | +54.1% |
| Q3 2020 | $3,497,000 | -3.6% | 370,100 | -8.6% | 0.18% | -10.8% |
| Q2 2020 | $3,629,000 | +26.3% | 405,000 | -10.2% | 0.20% | -1.0% |
| Q1 2020 | $2,873,000 | +75.9% | 451,000 | +131.2% | 0.20% | +122.8% |
| Q4 2019 | $1,633,000 | -27.8% | 195,100 | -22.0% | 0.09% | -32.8% |
| Q3 2019 | $2,263,000 | +19.7% | 250,100 | +42.4% | 0.14% | +18.1% |
| Q2 2019 | $1,891,000 | +27.0% | 175,600 | +12.5% | 0.12% | +26.1% |
| Q1 2019 | $1,489,000 | +292.9% | 156,100 | +373.0% | 0.09% | +253.8% |
| Q4 2018 | $379,000 | -85.5% | 33,000 | -78.6% | 0.03% | -83.0% |
| Q3 2018 | $2,619,000 | +137.9% | 154,500 | +99.4% | 0.15% | +131.8% |
| Q2 2018 | $1,101,000 | +189.7% | 77,500 | +287.5% | 0.07% | +175.0% |
| Q1 2018 | $380,000 | – | 20,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 6,000,000 | $66,540,000 | 6.69% |
| FIC CAPITAL INC | 787,529 | $8,734,000 | 3.47% |
| RA Capital Management | 1,220,209 | $13,532,000 | 1.36% |
| PRINCETON CAPITAL MANAGEMENT INC | 114,120 | $1,266,000 | 0.67% |
| Perceptive Advisors | 800,000 | $8,872,000 | 0.53% |
| Cormorant Asset Management, LP | 361,000 | $4,003,000 | 0.53% |
| Highlander Capital Management, LLC | 43,500 | $482,000 | 0.43% |
| APEX CAPITAL, LLC | 439,900 | $4,878,000 | 0.42% |
| WASATCH ADVISORS LP | 3,091,386 | $34,283,000 | 0.37% |
| Baker Brothers Advisors | 3,230,932 | $35,831,000 | 0.31% |